These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 20712263

  • 1. Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: a case series.
    d'Ettorre G, Barbarini G, Corti F, Gobber M, Pastecchia C, Ricci GL, Siciliano M, Annicchiarico BE, Vullo V.
    Eur Rev Med Pharmacol Sci; 2010 Jun; 14(6):551-4. PubMed ID: 20712263
    [Abstract] [Full Text] [Related]

  • 2. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R.
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [Abstract] [Full Text] [Related]

  • 3. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF.
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [Abstract] [Full Text] [Related]

  • 4. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B].
    Kim JM, Choe BH, Chu MA, Cho SM.
    Korean J Hepatol; 2009 Jun; 15(2):168-78. PubMed ID: 19581769
    [Abstract] [Full Text] [Related]

  • 5. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.
    Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Jeong ID, Bang SJ, Lee SH, Kim SR, Park NH.
    J Viral Hepat; 2012 Oct; 19(10):724-31. PubMed ID: 22967104
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients.
    Zhang X, Lin SM, Ye F, Chen TY, Liu M, Chen YR, Zheng SQ, Zhao YR, Zhang SL.
    J Viral Hepat; 2011 Jul; 18(7):e184-90. PubMed ID: 21692931
    [Abstract] [Full Text] [Related]

  • 11. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.
    Papatheodoridis G, Goulis J, Manolakopoulos S, Margariti A, Exarchos X, Kokkonis G, Hadziyiannis E, Papaioannou C, Manesis E, Pectasides D, Akriviadis E.
    J Hepatol; 2014 Jan; 60(1):62-8. PubMed ID: 24012614
    [Abstract] [Full Text] [Related]

  • 12. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
    Chen CH, Hung CH, Hu TH, Wang JH, Lu SN, Su PF, Lee CM.
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.
    Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, Dauvergne A, Cardoso AC, Asselah T, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P.
    J Hepatol; 2009 Jun; 50(6):1084-92. PubMed ID: 19376603
    [Abstract] [Full Text] [Related]

  • 15. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M, Xu B, Yao GB.
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [Abstract] [Full Text] [Related]

  • 16. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss.
    Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL.
    J Infect Dis; 2011 Aug 01; 204(3):415-8. PubMed ID: 21742840
    [Abstract] [Full Text] [Related]

  • 17. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
    Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U.
    Hepatology; 2010 Feb 01; 51(2):422-30. PubMed ID: 20049753
    [Abstract] [Full Text] [Related]

  • 18. [The clinic features and the short-term efficacy of entecavir treatment of the HBeAG negative acute-on-chronic hepatitis B liver failure].
    Shu X, Xu QH, Chen N, Zhang K, Li G.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Dec 01; 22(6):481-3. PubMed ID: 19544652
    [Abstract] [Full Text] [Related]

  • 19. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
    Boglione L, Cardellino CS, De Nicolò A, Cariti G, Di Perri G, D'Avolio A.
    J Med Virol; 2014 Nov 01; 86(11):1845-50. PubMed ID: 25131947
    [Abstract] [Full Text] [Related]

  • 20. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL.
    Gastroenterology; 2010 Aug 01; 139(2):491-8. PubMed ID: 20381492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.